Faruk Recep Özalp

Dr. Faruk Recep Özalp

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2024 in BMC Cancer
Verified
Journal Article
Open access
PDF file
FÖFaruk Recep Özalp
Faruk Recep Özalp
KYKutsal Yörükoğlu
Kutsal Yörükoğlu
EYEda Çalışkan Yıldırım
Eda Çalışkan Yıldırım
MUMehmet Uzun
Mehmet Uzun
HSHüseyin Salih Semiz
Hüseyin Salih Semiz
Renal cell carcinoma (RCC) is characterised by its immunogenic and proangiogenic nature and its resistance to conventional therapies. The advent of immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) has significantly improved patient survival, but resistance to these treatments remains a challenge. B7-H3, a potential immune checkpoint, has been implicated in modulating the tumour microenvironment and immune escape mechanisms in RCC. Immunohistochemical analysis of B7-H3 expression was performed in 84 metastatic RCC patients. Tissue microarrays and separate sections of formalin-fixed paraffin-embedded tissue were used for immunohistochemical staining. Membranous staining of the tumor cells was scored and statistical analyses were performed to assess the correlation between B7-H3 expression and treatment outcome. B7-H3 expression was absent in 31% of patients, while 33.3% had a score of 1+, 31% had 2+, and 4.8% had 3+. High B7-H3 expression correlated with poorer OS (20 months vs. 45 months, p = 0.012). In patients receiving nivolumab, those with high B7-H3 expression had shorter PFS (2 months vs. 8 months, p = 0.037) and OS (17 months vs. 51 months, p = 0.01). B7-H3 expression was the only factor significantly affecting PFS and OS in multivariate analysis. High B7-H3 expression is associated with poorer survival outcomes and reduced response to nivolumab in metastatic RCC patients. B7-H3 may serve as a predictive biomarker for immunotherapy response. Future studies should explore targeting B7-H3 in combination with existing therapies to enhance treatment efficacy.

10 September 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
FÖFaruk Recep Özalp
Faruk Recep Özalp
EHECE ŞAHİN HAFIZOĞLU
ECE ŞAHİN HAFIZOĞLU
AAAhmet Melih Arslan
Ahmet Melih Arslan
MÇMehmet Çakmak
Mehmet Çakmak
SBSedat Biter
Sedat Biter
AKAziz Karaoğlu
Aziz Karaoğlu
Background: The Meet-URO score combines the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria with neutrophil-to-lymphocyte ratio (NLR) and bone metastasis status. Although developed in immune checkpoint inhibitor (ICI) cohorts, its performance among patients receiving first-line tyrosine kinase inhibitor (TKI) monotherapy is uncertain. Methods: We performed a multicenter, retrospective cohort study of 301 adults with histologically confirmed metastatic renal cell carcinoma (mRCC) treated with first-line TKI monotherapy (sunitinib, pazopanib, or cabozantinib) between 2008 and 2025 across five tertiary centers in Turkey. The primary endpoint was overall survival (OS). Meet-URO was calculated at treatment start and analyzed as prespecified risk strata (0–4, 5–8, 9). Kaplan–Meier estimates, Cox models, and Harrell’s C-index assessed discrimination, with bootstrapped 95% CIs. Results: Median follow-up was 40 months; median OS (mOS) was 25 months (95% CI, 21–29) and median progression-free survival was 10 months (95% CI, 8–12). Meet-URO stratified OS: 41 months for scores 0–4, 21 months for 5–8, and 7 months for 9 (log-rank p < 0.001). In multivariable analysis, Meet-URO remained independently prognostic (HR 1.73 for 5–8 vs. 0–4; HR 3.57 for 9 vs. 0–4; both p < 0.001). Discrimination was modest (C-index 0.722) and slightly lower than IMDC (C-index 0.745). NLR ≥ 3.2 was associated with inferior OS (19 vs. 37 months; p < 0.001). Bone metastasis was not significantly associated with OS (p = 0.27). Conclusions: Meet-URO is a valid prognostic tool for mRCC patients treated with first-line TKIs and identifies an ultra-high-risk subgroup (score = 9) with poor survival. While not superior to IMDC, Meet-URO may offer complementary risk information to support clinical monitoring and trial referral, particularly in settings where ICI combinations are restricted.

18 May 2026 in Medicina
Verified
Journal Article
Open access
PDF file
MSMustafa Seyyar
Mustafa Seyyar
PŞPervin Can Şancı
Pervin Can Şancı
ASAbdullah Sakin
Abdullah Sakin
ABAyberk Bayramgil
Ayberk Bayramgil
ÖKÖzgecan Dülgar Kaya
Özgecan Dülgar Kaya
UKUmut Kefeli
Umut Kefeli
Background and Objectives: Perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) is the standard of care for resectable gastric and gastroesophageal junction adenocarcinoma; however, up to 50% of patients develop metastatic recurrence. These patients have prior exposure to platinum and taxane agents, and optimal first-line treatment in the metastatic setting remains undefined. This study aimed to characterize real-world treatment patterns and outcomes in patients progressing after perioperative FLOT, focusing on relapse timing and HER2 status. Materials and Methods: This retrospective, multicenter cohort study included 296 patients from 31 centers across Türkiye, stratified into early relapse (≤6 months, n = 114) and late relapse (>6 months, n = 182) groups. Survival analyses were performed using the Kaplan-Meier method and Cox proportional hazards regression. Primary endpoints were progression-free survival (PFS) and overall survival (OS). Results: Median PFS and OS for the entire cohort were 6 and 9 months, respectively. Early relapsers had significantly shorter median PFS (4 vs. 6 months, p = 0.029) and OS (8 vs. 12 months, p = 0.047); however, early relapse timing did not retain independent prognostic significance on multivariable analysis. No significant difference in PFS or OS was observed between cytotoxic chemotherapy regimens in either relapse group. HER2 positivity was the only independent predictor of improved PFS on multivariable Cox analysis (HR 0.48, 95% CI 0.29–0.81; p = 0.006). In the late relapse group, trastuzumab-based chemotherapy achieved a median PFS of 14 months and OS of 18 months, significantly superior to all cytotoxic regimens (PFS p = 0.007; OS p = 0.029). Conclusions: In patients progressing after perioperative FLOT, cytotoxic chemotherapy regimen selection did not demonstrate a statistically significant survival difference in this retrospective cohort, regardless of relapse timing. HER2 positivity is the dominant predictive biomarker, and trastuzumab-based therapy suggests a potential survival benefit that warrants prospective validation. Comprehensive biomarker profiling at metastatic diagnosis and prospective trials designed for this post-FLOT population are needed to establish evidence-based treatment standards.

9 May 2025 in Medicina
Verified
Journal Article
Open access
PDF file
FÖFaruk Recep Özalp
Faruk Recep Özalp
KYKutsal Yörükoğlu
Kutsal Yörükoğlu
EYEda caliskan yildirim
Eda caliskan yildirim
MUMehmet Uzun
Mehmet Uzun
EDErkut Demirciler
Erkut Demirciler
HSHuseyin Salih Semiz
Huseyin Salih Semiz
Background and Objectives: Renal cell carcinoma (RCC) is a biologically heterogeneous malignancy, and traditional prognostic models often fail to provide accurate risk stratification. B7-H3 (CD276), an immune checkpoint molecule, has been implicated in RCC progression but remains underexplored as a prognostic biomarker. Materials and Methods: This retrospective study analyzed 52 patients with localized RCC who underwent nephrectomy. Immunohistochemical staining was used to assess B7-H3 expression. A novel prognostic scoring system, the Renal Immune Prognostic Index (RIPI), incorporating B7-H3 expression, tumor necrosis, tumor grade, and pathological staging, was developed and validated. Kaplan–Meier survival analysis and Cox proportional hazard models were employed to evaluate disease-free survival (DFS) and overall survival (OS). Results: High B7-H3 expression was significantly associated with shorter DFS (12 vs. 54 months; p = 0.001) and OS (70 vs. 123 months; p = 0.002). The RIPI demonstrated strong prognostic performance, stratifying the patients into distinct risk groups with a C-index of 0.82. The high-risk patients had a median DFS of 14 months, compared with 125 months in the low-risk group (p < 0.001). Conclusions: B7-H3 expression serves as a significant prognostic biomarker in localized RCC, correlating with poorer survival outcomes. The integration of B7-H3 into the RIPI enhances risk stratification by incorporating both molecular and pathological features. These findings support the incorporation of immune biomarkers into clinical practice and highlight B7-H3 as a potential target for novel therapeutic strategies in RCC.

25 May 2026 in Discover Oncology
Verified
Journal Article
Open access
FÖFaruk Recep Özalp
Faruk Recep Özalp
HEHalil İbRahim Ellez
Halil İbRahim Ellez
AAAhmet Melih Arslan
Ahmet Melih Arslan
EDErkut Demirciler
Erkut Demirciler
SGSavaş Gökçek
Savaş Gökçek
AKAziz Karaoğlu
Aziz Karaoğlu
Despite recent advances in bladder cancer treatment, therapeutic resistance remains a major clinical challenge, highlighting the need for novel molecular targets. In this study, we performed an integrative in silico analysis to evaluate the prognostic significance and molecular landscape of CD276 (B7-H3) in bladder cancer. Analyses of TCGA and GTEx datasets demonstrated significant upregulation of CD276 in tumor tissues compared with normal controls, with expression increasing across advanced clinical stages. Kaplan-Meier and univariate Cox regression analyses showed that high CD276 expression was associated with poorer overall survival. Functional enrichment analyses linked CD276 to PI3K-Akt signaling and a myeloid/macrophage-enriched immune microenvironment, including M2-like macrophage signatures. Pharmacogenomic analyses across large cancer cell line panels further suggested a resistance-associated phenotype in CD276 high models including reduced sensitivity to PI3K/mTOR inhibitors and several cytotoxic agents used in urothelial cancer treatment. Collectively, these findings support CD276 as a promising biomarker associated with aggressive biology and provide a rationale for future experimental and clinical validation of CD276 directed therapeutic strategies in advanced bladder cancer.

15 August 2026 in Journal of Medicine and Palliative Care
Verified
Journal Article
Open access
FÖFaruk Recep Özalp
Faruk Recep Özalp
ÖYÖzge Yetginoğlu
Özge Yetginoğlu
ŞSŞerife Sivridemir
Şerife Sivridemir
EDErkut Demirciler
Erkut Demirciler
OAOktay halit Aktepe
Oktay halit Aktepe
AKAziz Karaoğlu
Aziz Karaoğlu
Aims: To analyze the clinicopathological features and survival outcomes of early-onset colon cancer (EOCC,